Home › Compound Library › Apixaban (Eliquis)

Apixaban (Eliquis)

Anticoagulantprescriptionoral · inferred

Direct oral anticoagulant (DOAC) and selective factor Xa inhibitor; inhibits both free and clot-bound factor Xa. Rapid absorption (tmax 3-4h), ~50% oral bioavailability, primarily hepatically metabolized via CYP3A4. Does not require dose adjustments for renal impairment (only 27% renal clearance). No food effect. Fixed dosing without need for therapeutic drug monitoring. Approved for stroke prevention in nonvalvular atrial fibrillation, VTE treatment/prevention. Lower bleeding risk profile than warfarin. Potential reversal with apixaban-specific antidote (apixaban reversal agent under development).

Projected serum levels — 5 mg, once daily

Apixaban (Eliquis)
Apixaban (Eliquis) modeled serum levels, 5 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 1.3 2.5 3.8 5 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1
Apixaban (Eliquis) modeled serum levels with a loading dose of 6.2 mg, then 5 mg once daily The first dose is larger so levels approach steady state faster. 0 1.3 2.5 3.8 5 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 5 mg once daily (oral).

Loading schedule: 6.2 mg on day 1, then 5 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~1 days: peak ≈ 2.6 mg, trough ≈ 0.57 mg body load. Population-based estimate over 15 days for a 5 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Anticoagulant
Route modeled
Oral
Model confidence
inferred
Half-life
12 h
Common dose
5 mg
Suggested maximum
10 mg/day
Reference dose range
2.5–10 mg (single dose)
Suggested cadence
once daily
Validated against
10 mg oral — Cmax 0.17 mg/L at 3 h

Documented interactions

  • contraindicated
    Efavirenz (Sustiva) + Apixaban (Eliquis) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Apixaban (Eliquis) AUC by ~0.19x

  • contraindicated
    Rifampin + Apixaban (Eliquis) CYP induction

    Rifampin inducer of CYP3A4 predicted to change Apixaban (Eliquis) AUC by ~0.19x

  • danger
    Carbamazepine (Tegretol) + Apixaban (Eliquis) CYP induction

    Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change Apixaban (Eliquis) AUC by ~0.29x

  • danger
    Clarithromycin (Biaxin) + Apixaban (Eliquis) CYP inhibition

    Clarithromycin (Biaxin) mechanism_based of CYP3A4 predicted to change Apixaban (Eliquis) AUC by ~2.29x

  • danger
    Dasatinib (Sprycel) + Apixaban (Eliquis) CYP inhibition

    Dasatinib (Sprycel) time_dependent_inhibitor of CYP3A4 predicted to change Apixaban (Eliquis) AUC by ~2.00x

  • danger
    Diltiazem + Apixaban (Eliquis) CYP inhibition

    Diltiazem mechanism_based of CYP3A4 predicted to change Apixaban (Eliquis) AUC by ~2.29x

Serum checks 90 modeled interaction pairings for apixaban (eliquis) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects Frost C et al. · British Journal of Clinical Pharmacology, 2013 DOI

    First-in-human PK study establishing apixaban single-dose safety, bioavailability (~50%), tmax 3-4h, and no clinically meaningful food effect in healthy volunteers.

  2. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects Frost C et al. · British Journal of Clinical Pharmacology, 2013 DOI

    Multiple ascending-dose study confirming linear apixaban PK, no accumulation with repeated dosing, predictable FXa inhibition, and good tolerability up to 10 mg.

  3. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review Kearon C et al. · Clinical Pharmacokinetics, 2019 DOI

    Comprehensive review of apixaban pharmacokinetics, pharmacodynamics, drug interactions (minimal with most agents), efficacy/safety in clinical trials, and dosing strategies.

3 published studies referenced in the app, each with a plain-language summary.